Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis
NCT ID: NCT02499315
Last Updated: 2016-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
32 participants
INTERVENTIONAL
2015-04-30
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
NCT00293826
Safety and Efficacy of AMG 827 in Subjects With RA
NCT01059448
Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis
NCT03156023
Long-Term Assessment of Safety and Physical Function With AMG 108 in RA
NCT00369473
Phase 2 AMG 714 in Rheumatoid Arthritis
NCT00433875
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMG 357
AMG 357
Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Placebo
Placebo
Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMG 357
Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Placebo
Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Rheumatoid arthritis present for ≥ 3 months.
* Global functional class I, II, or III.
* History of or positive for, Rheumatoid Arthritis
* Taking methotrexate consecutively for ≥ 12 weeks and on a stable dose at 10-25 mg weekly.
* Subjects currently taking NSAIDs or oral corticosteroids.
* Normal ECG values
* Immunizations up to date.
Exclusion Criteria
* Sensitivity to any of the products or components to be administered.
* Malignancy within 3 years
* Presence of recurrent or chronic infections
* Evidence of infections within the 30 days prior to randomization
* Presence of a serious infection
* Prosthetic joint infection within 3 years or native joint infection within 1 year
* History of exposure to tuberculosis without a history of prophylactic treatment
* Class IV RA.
* Felty's syndrome
* Chronic pelvic pain or hemorrhagic ovarian cyst within 3 years
* Any bleeding disorder that is clinically significant
* Low white blood cell or neutrophil count
* Elevated serum creatinine clearance
* Low hemoglobin and platelet count
* Received live vaccines within 3 months of first dose
* Alcohol and/or substance abuse within past 12 months
* Blood donation within 60 days
* Positive urine screen for drugs of abuse
* Any prior use of rituximab in the last 6 months (or other B cell depleting agents) and CD19 levels \< lower limits of normal
* Use of a weekly or bimonthly biologic within 2 weeks or monthly biologic agents within 4 weeks
* Corticosteroid injections for acute RA flare within 4 weeks
* Grapefruit juice or grapefruit containing products within 7 days of first dose.
* All herbal medicines, vitamins, and supplements within the 30 days
* The use of any experimental/investigational biologic DMARD unless off agent for 3 months; or off for 6 months for B cell depleting agents
* Known GI disease or GI procedures
* Women of reproductive potential who are unwilling to practice birth control
* Women who are pregnant/lactating/breastfeeding
* Subject with IgG levels \< lower limit of normal at screening
25 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Duncansville, Pennsylvania, United States
Research Site
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20110247
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.